The conversation discusses hair loss linked to BDNF-increasing nootropics like Semax and Lions Mane. Suggested topical treatments include capsaicin, beta-glucan, and ginseng to counteract TGF-B activation.
After 11 years on Finasteride, a user's hair is thinning again, suggesting hair may become more sensitive to DHT with age. They plan to introduce Dutasteride once a week, as they cannot tolerate Minoxidil.
Combining Minoxidil with Peppermint or Rosemary Oil may enhance hair growth. Users discuss the potential benefits of this combination for treating hair loss.
Androgenetic alopecia is caused by DHT affecting hair growth. Finasteride and minoxidil are used to manage hair loss by blocking DHT and promoting hair growth.
The post discusses a user's six-year progress with finasteride and a Follicular Unit Transplant (FUT) for hair loss. The user shared before and after photos in reverse order, leading to confusion, but overall, the community responded positively to the user's hair regrowth.
Safflower oil is suggested as an alternative to minoxidil for hair growth, with benefits including scalp conditioning and hair strength enhancement. Studies indicate it may also reverse scalp dermatitis, alopecia, and prevent premature grayness.
A human trial involving verteporfin for hair regeneration, with the results showing some regrowth of 1-2 hairs in an area where a follicular unit was extracted. The conversation also suggested that future studies should involve higher doses and more frequent injections.
SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.
Hair regrowth in transfems is more effective due to hormonal changes, specifically estrogen, which keeps hair in growth phase longer. Treatments mentioned include anti-androgens, sex hormones, and DHT blockers like finasteride.
A user asked if anyone who didn't respond to minoxidil saw improvement after adding tretinoin. One person replied they saw hair growth on their hairline after using a combination of minoxidil, finasteride, and tretinoin, suggesting tretinoin may have made them respond to minoxidil.
A user shared their year-long hair loss treatment using minoxidil, microneedling, and scalp massages, reporting moderate hair growth and stabilization. They suggest starting early with less harmful methods and consider adding finasteride or dutasteride if needed.
Microneedling for hair restoration involves daily use of a 0.3 mm device and weekly use of a 0.5 mm device. Combining microneedling with Minoxidil can enhance hair growth.
Oral minoxidil is considered more effective for hair regrowth than topical minoxidil, but it carries higher risks. Combining microneedling with topical minoxidil can enhance absorption, but oral minoxidil with microneedling shows significant results.
The user has been on finasteride for 4.5 years and minoxidil for 10 years, maintaining hair but not regrowing much on the crown and temples. They are considering using a dermastamp more frequently and possibly trying RU58841, but are hesitant about dutasteride due to concerns about side effects and DHT suppression.
Some individuals do not respond to oral minoxidil for hair loss, despite it generally working by improving blood flow to hair follicles. Factors like metabolism, drug interactions, and individual variations in the drug's activation may influence its effectiveness.
The conversation is about future hair loss treatments. Current treatments mentioned include finasteride, minoxidil, and RU58841, with potential future treatments like GT20029, TDM-105795, JW0061, and follicle cloning.
A dental technician claims malocclusion causes pattern hair loss due to poor scalp circulation. Users debate this, noting treatments like finasteride, minoxidil, and microneedling focus on DHT and blood flow.
The user has been using finasteride and oral minoxidil for hair loss but hasn't seen improvement and is quitting nicotine and caffeine to see if it helps. Some believe quitting nicotine improved their hair health due to better blood flow, while others are skeptical about the impact of blood flow on hair loss.
Male androgenetic alopecia is commonly treated with topical minoxidil and oral finasteride, both requiring continuous use. Other options include hair restoration surgery, dutasteride, light therapy, and camouflaging agents.
Exercise, especially leg workouts, combined with finasteride and minoxidil, may enhance hair regrowth. Cold exposure, like cold showers, might further boost results.
User shared 12-month hair loss progress using oral minoxidil, oral dutasteride, and 2% ketoconazole shampoo. They detailed their medication regimen and dosages.
The conversation is about using a Dr. Pen for microneedling on a widow's peak, with advice to use a depth of 1.25mm and hold it in place for 10 seconds. The user is also using minoxidil.
A user shared their positive experience with a hair transplant at Dr. Resul Yaman Hair Clinic in Istanbul, including before and after photos. They are considering taking oral Minoxidil post-operation but are avoiding Finasteride due to side effects.
The user shared a 3.5-year hair loss treatment journey using 1 mg finasteride daily and minoxidil foam, noting significant improvement, especially in the third year. They also mentioned using Nizoral shampoo twice a week and supplements like vitamin D3, biotin, and omega 3 and 6.
The efficacy of microneedling for hair regrowth as either a stand-alone therapy or adjunct to Minoxidil, and whether Tretinoin is a safer and more effective option. Replies include personal accounts from users who have had success with microneedling in combination with minoxidil and peptide serums, as well as considerations of technique, depth, and potential scarring.
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.